There are still relatively few child-friendly antimalarial formulations available today. As a result, many children still receive adult formulations – usually tablets that need to be crushed and which taste bitter, causing children to either refuse the medicine or to vomit on administration. This can lead to underdosing, resulting in incomplete cure, which in-turn can promote drug resistance.
MMV and partners prioritize the development of child-friendly antimalarials and the generation of evidence of their use in real-life settings to support increased uptake.
More information in an interview with Dr Ghyslain Mombo-Ngoma, Head of Clinical Operations Department, CERMEL, Gabon.